Johnson & Johnson reported a strong first quarter of fiscal 2026 with revenue growth driven by its Innovative Medicines segment, particularly oncology products like CARVYKTI and DARZALEX. However, the company faces escalating regulatory scrutiny and government investigations, as disclosed in its recent 10-Q, posing potential risks including significant fines and compliance costs. Despite these headwinds, J&J’s diversified business model, substantial R&D investments, and broad global footprint underpin its competitive moat. Investors should monitor product pipeline approvals, ongoing litigation outcomes, and capital allocation moves as key catalysts.